Abstract
Chimaerism of FACS-sorted leucocyte subsets (CD14+, CD15+, CD3−/56+, CD3+/4+, CD3+/8+, CD19+) was monitored prospectively between days +14 and +100 in 39 children undergoing allogeneic stem cell transplantation with reduced intensity-conditioning regimens. Cell subsets exceeding 1% of nucleated cells were subject to cell sorting. Chimaerism was analysed by dual-colour FISH and/or by short tandem repeat-polymerase chain reaction. The chimaerism pattern on day +28 was evaluated with regard to its correlation with graft rejection. Of 39 patients, nine patients had donor chimaerism (DC) in all subsets. Mixed/recipient chimaerism (MC/RC) was detectable within T cells in 62%, within NK cells in 39% and within monocytes and granulocytes in 38% of the patients. The correlation of secondary graft rejection with the chimaerism pattern on day +28 revealed the strongest association between RC in NK-cells (P<0.0001), followed by T cells (P=0.001), and granulocytes and monocytes (P=0.034). Notably, patients with RC in T cells rejected their graft only if MC or RC was also present in the NK-cell subset. By contrast, none of the children with DC in NK cells experienced a graft rejection. These observations suggest that, in the presence of recipient T-cell chimaerism, the chimaerism status in NK-cells on day +28 might be able to identify patients at high risk for late graft rejection.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gluckman E, Bussel A, Benbunan M, Broquet M, Schaison G, Dausset J et al. Treatment of bone marrow aplasia by allogenic bone marrow grafts. Nouv Presse Med 1975; 19: 1177–1182.
Hansen G, Dupont B, Faber V, Jakobson B, Juhl F, Nielsen L et al. Lymphocyte chimerism after bone marrow transplantation. Surface markers and in vitro function of donor and recipient lymphocyte subpopulations. Scand J Immunol 1977; 6: 299–303.
Starling K, Faletta J, Fernbach D . Immunologic chimerism as evidence of bone marrow graft acceptance in an identical twin with acute lymphocytic leukemia. Exp Hematol 1975; 3: 244–248.
Hancock JP, Goulden NJ, Oakhill A, Steward CG . Quantitative analysis of chimerism after allogeneic bone marrow transplantation using immunomagnetic selection and fluorescent microsatellite PCR. Leukemia 2003; 17: 247–251.
Lapointe C, Forest L, Lussier P, Busque L, Lagace F, Perrault C et al. Sequential analysis of early hematopoietic reconstitution following allogeneic bone marrow transplantation with fluorescence in situ hybridization (FISH). Bone Marrow Transplant 1996; 17: 1143–1148.
Lion T . Summary: reports on quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection. Leukemia 2003; 17: 252–254.
Scharf S, Smith A, Hansen J, McFarland C, Erlich H . Quantitative determination of bone marrow transplant engraftment using fluorescent polymerase chain reaction primers for human identity markers. Blood 1995; 85: 1954–1963.
Bader P, Beck J, Frey A, Schlegel P, Hebarth H, Handgretinger R et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487–495.
Casado L, Steegmann J, Pico M, Requena M, Ramirez M, Madero L et al. Study of chimerism in long-term survivors after bone marrow transplantation for severe acquired aplastic anemia. Bone Marrow Transplant 1996; 18: 405–409.
Frankel W, Chan A, Corringham R, Shepherd S, Rearden A, Wang-Rodriguez J . Detection of chimerism and early engraftment after allogeneic peripheral stem cell or bone marrow transplantation by short tandem repeats. Am J Hematol 1996; 52: 281–287.
Amrolia P, Vulliamy T, Vassiliou G, Lawson SE, Bryon J, Kaeda J et al. Analysis of chimerism in thalassaemic children undergoing stem cell transplantation. Br J Haematol 2001; 114: 219–225.
Andreani M, Nesci S, Lucarelli G, Tonucci P, Angelucci E, Persini B et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25: 401–404.
Gomez J, Garcia M, Serrano J, Sanchez J, Falcon M, Castillejo J et al. Chimerism analysis in long term survivors patients after bone marrow transplantation for severe aplastic anemia. Haematologica 1997; 82: 588–591.
Hill RS, Petersen FB, Storb R, Appelbaum FR, Doney K, Dahlberg S et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood 1986; 67: 811–816.
Mital M, Curtis A, Spencer V, Barge D, Skinner R . Delayed engraftment and mixed chimerism after HLA-identical sibling donor BMT in Fanconi anaemia. Bone Marrow Transplant 1999; 24: 201–204.
McSweeney P, Storb R . Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 2001; 5: 192–203.
Shimoni A, Nagler A . Non-myeloablative stem cell transplantation (NST): chimerism testing as a guidance for immune-therapeutic manipulations. Leukemia 2001; 15: 1967–1975.
Carella AM, Champlin R, Slavin S, McSweeney PA, Storb R . Mini-allografts: ongoing trials in humans. Biol Blood Marrow Transplant. 2000; 25: 345–350.
Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med 2001; 344: 881–888.
Amrolia P, Gaspar HB, Hassan A, Webb D, Jones A, Sturt N et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000; 96: 1239–1246.
Childs R, Clave E, Contentin N, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234–3241.
Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S et al. Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia 1999; 13: 2060–2069.
Mackinnon S, Barret L, Heller G, O'Reilly R . Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia. Blood 2001; 83: 3409–3416.
Mattsson J, Uzunel M, Remberger M, Ringden O . T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2001; 71: 433–439.
Maury S, Jouault H, Kuentz M, Vernant JP, Tulliez M, Cordonnier C et al. Chimerism analysis by lineage-specific fluorescent polymerase chain reaction in secondary graft failure after allogeneic stem cell transplantation. Transplantation 2001; 71: 374–380.
Niiya H, Kanda Y, Saito T, Ohnishi T, Kanai S, Kawano Y et al. Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan. Haematologica 2001; 86: 1071–1074.
Winiarski J, Mattson J, Gustafsson A, Wester D, Borgstrom B, Ringden O et al. Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation. Pediatr Transplant 1998; 2: 150–156.
Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate-mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.
Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.
Fritsch G, Printz D, Stimpfl M, Dworzak M, Witt V, Potschger U et al. Quantification of CD34+ cells: comparison of methods. Transfusion 1997; 37: 775–784.
Schraml E, Daxberger H, Watzinger F, Lion T . Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Vienna experience. Leukemia 2003; 17: 224–227.
Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2001; 7: 473–485.
van Leeuwen JE, van Tol MJ, Bodzinga BG, Wijnen JT, van der KM, Joosten AM et al. Detection of mixed chimerism in flow-sorted cell subpopulations by PCR-amplified VNTR markers after allogeneic bone marrow transplantation. Br J Haematol 1991; 79: 218–225.
Bader P, Holle W, Klingebiel T, Handgretinger R, Benda N, Schlegel P et al. Mixed hematopoietic chimerism after alogeneic marrow transplantation: the impact of quantitative PCR analysis for prediction of relapse and graft rejection in children. Bone Marrow Transplant 2001; 19: 697–702.
Schattenberg A, De Witte T, Salden M, Vet J, Van Dijk B, Smeets D et al. Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. Blood 1989; 73: 1367–1372.
Lion T, Daxberger H, Dubovsky J, Filipcik P, Fritsch G, Printz D et al. Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 2001; 15: 307–310.
Mattsson J, Uzunel M, Tammik L, Aschan J, Ringden O . Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia 2001; 15: 1976–1985.
Thiede C, Bornhauser M, Oelschlagel U, Brendel C, Leo R, Daxberger H et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification short tandem repeat-markers. Leukemia 2001; 15: 293–302.
Zetterquist H, Mattson J, Uzunel M, Nasman-Bjork I, Svenberg P, Bayat G et al. Mixed chimerism in the b cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. Bone Marrow Transplant 2001; 25: 843–851.
Battaglia M, Anreani M, Manna M, Nesci S, Tonucci P, Persini B et al. Coexistence of two functioning T-cell repertoires in healthy ex-Thalassemics bearing a persistent mixed chimerism years after bone marrow transplantation. Blood 1999; 94: 3432–3438.
Haddad E, Le Deist F, Aucouturier P, Cavazzana-Calvo M, Blanche S, De Saint Basile G et al. Long-term chimerism and b-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B-cells: a single-center study of 22 patients. Blood 1999; 94: 2923–2930.
Passweg JR, Meyer-Monard S, Gregor M, Favre G, Heim D, Ebnoether M et al. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant 2002; 30: 267–271.
Perez-Simon JA, Caballero D, Diez-Campelo M, Lopez-Perez R, Mateos G, Canizo C et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423–1431.
McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molidrem J, Chauncey TR et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.
Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E . Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87: 3984–3992.
Sykes M, Preffer F, McAfee S, Saidman S, Weymouth D, Andrews D et al. Mixed lymphohematopoietic chimerism and graft versus lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone marrow transplantation. Lancet 1999; 16: 1755–1759.
Schaap N, Schattenberg A, Mensink E, Preijers F, Hillegers M, Knops R et al. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation. Leukemia 2002; 16: 13–21.
Gyger M, Baron C, Forest L, Lussier P, Lagace F, Bissonnette I et al. Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs-host disease. Exp Hematol 1998; 26: 426–434.
Mackinnon S, Barnett L, Bourhis JH, Black P, Heller G, O'Reilly RJ . Myeloid and lymphoid chimerism after T-cell-depleted bone marrow transplantation: evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 1992; 80: 3235–3241.
Valcarcel D, Martino R, Caballero D, Mateos M, Perez-Simon J, Canals C et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplant 2003; 31: 387–392.
Kreiter S, Winkelmann N, Schneider PM, Schuler M, Fischer T, Ullmann AJ et al. Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 2001; 28: 157–161.
Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la RJ, Brunet S et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383–387.
Görner M, Kordelas L, Thalheimer M, Luft T, Pfeiffer S, Ustaoglu F et al. Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine. Bone Marrow Transplant 2002; 29: 621–624.
Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108–3114.
Bornhauser M, Thiede C, Platzbecker U, Jenke A, Helwig A, Plettig R et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001; 7: 2254–2262.
Bertrand Y, Landais P, Friedrich W, Gerritson E, Morgan G, Fasth A et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the European society for immunodeficiency. J Pediatr 1999; 134: 740–748.
Kawai T, Wee SL, Bazin H, Latinne D, Phelan J, Boskovic S et al. Association of natural killer cell depletion with induction of mixed chimerism and allograft tolerance in non-human primates. Transplantation 2000; 70: 368–374.
Lee LA, Sergio JJ, Sykes M . Natural killer cells weakly resist engraftment of allogeneic, long-term, multilineage-repopulating hematopoietic stem cells. Transplantation 1996; 61: 125–132.
Neipp M, Gammie JS, Exner BG, Li S, Chambers WH, Pham SM et al. A partial conditioning approach to achieve mixed chimerism in the rat: depletion of host natural killer cells significantly reduces the amount of total body irradiation required for engraftment. Transplantation 1999; 68: 369–378.
Tiberghien P, Longo DL, Wine JW, Alvord WG, Reynolds CW . Anti-asialo GM1 antiserum treatment of lethally irradiated recipients before bone marrow transplantation: evidence that recipient natural killer depletion enhances survival, engraftment, and hematopoietic recovery. Blood 1990; 76: 1419–1430.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.
Bornhauser M, Thiede C, Brendel C, Geissler G, Oelschlagel U, Neubauer A et al. Stable engraftment after megadose blood stem cell transplantation across the HLA barrier: the case for natural killer cells as graft-facilitating cells. Transplantation 1999; 68: 87–88.
Murphy WJ, Koh CY, Raziuddin A, Bennett M, Longo DL . Immunobiology of natural killer cells and bone marrow transplantation: merging of basic and preclinical studies. Immunol Rev 2001; 181: 279–289.
Shilling H, McQueen K, Cheng N, Shizuru J, Negrin R, Parham P . Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730–3740.
Farag S, Fehniger T, Ruggeri L, Velardi A, Caliguri M . Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935–1947.
Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002; 63: 271–280.
D'Orazio J, Burke J, Stein-Streilein J . Staphylococcal Enterotoxin B activates purified NK cells to secrete IFN-y but requires T lymphocytes to augment NK cytotoxicity. J Immunol 1994; 154: 1014–1023.
Groh V, Rhinehart R, Randolph-Habecker J, Topp M, Riddell S, Spies T . Costimulation of CDaβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255–260.
Johnson T, Hong S, Van Kaer L, Koezuka Y, Graham B . NK T cells contribute to expansion of CD8+ T cells and amplification of antiviral immune responses to respiratory syncytial virus. J Virol 2002; 76: 4294–4303.
Das S, Varalakshmi C, Kumari A, Patel M, Khar A . Target cell induced activation of NK cells in vitro: cytokine production and enhancement of cytotoxic function. Cancer Immunol Immunother 2001; 50: 428–436.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matthes-Martin, S., Lion, T., Haas, O. et al. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 17, 1934–1942 (2003). https://doi.org/10.1038/sj.leu.2403087
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403087
Keywords
This article is cited by
-
Chimerism analysis for clinicians: a review of the literature and worldwide practices
Bone Marrow Transplantation (2022)
-
Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation
Leukemia (2012)
-
The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation
Leukemia (2012)
-
Enrichment of cell subpopulations applying automated MACS technique: purity, recovery and applicability for PCR-based chimerism analysis
Bone Marrow Transplantation (2010)